Genetic variation in coronary heart disease and myocardial infarction: Methodological overview and clinical evidence

Pharmacogenomics

Volumn 1, Issue 1, 2000, Pages 73-94

  Winkelmann, Bernhard R ^a,c   Hager, Joerg ^b  

^a Herzzentrum   (Germany)

^b CENTRE NATIONAL DE GÉNOTYPAGE   (France)

^c KLINIKUM LUDWIGSHAFEN   (Germany)

Author keywords

Cardiovascular; Coronary artery disease; Genome; Haplotype; Linkage analysis; Myocardial infarction; Polymorphism

Indexed keywords

CORONARY ARTERY DISEASE; GENETIC LINKAGE; GENETIC POLYMORPHISM; GENETICS; HEART INFARCTION; HUMAN; METABOLISM; PATHOPHYSIOLOGY; REVIEW;

CORONARY DISEASE; HUMANS; LINKAGE (GENETICS); MYOCARDIAL INFARCTION; POLYMORPHISM, GENETIC;

EID: 0034139722     PISSN: 14622416     EISSN: None     Source Type: Journal    
DOI: 10.1517/14622416.1.1.73     Document Type: Review

References (99)

1. VOGEL RA, BERGER H: Epidemiology and prevention of coronary heart disease. In: Book 1 - Adult Clinical Cardiology Self-Assessment Program. American College of Cardiology (1999).
2. TUNSTALL-PEDOE H, KUULASMAA K, AMOUYEL P, ARWEILER D, RAJAKANGAS A-M, PAJAK A (FOR THE WHO MONICA PROJECT): Myocardial infarction and coronary deaths in the World Health Organization MONICA Project - registration procedures, event rates, and case-fatality rates in 38 populations from 21 countries in four continents. Circulation (1994) 90:583-612.
3. http://www.amheart.org/heart_and_stroke_A-Z_guide AMERICAN HEART ASSOCIATION HEART AND STROKE FACTS: American Heart Association, Dallas, USA (1999).
4. SLACK J, EVANS KA: The increased risk of death from ischemic heart disease in first degree relatives of 121 men and 96 women with ischemic heart disease. J. Med. Genet. (1966) 3:239-257.
5. MARENBERG ME, RISCH N, BERKMAN LF, FLODERUS B, DEFAIRE U: Genetic susceptibility to death from coronary heart disease in a study of twins. New Engl. J. Med. (1994) 330:1041-1046.
6. VLIETSTRA RE, KRONMAL RA, FRYE RL, SETH AK, TRISTANI FE, KILLIP III T: Factors affecting the extent and severity of coronary artery disease in patients enrolled in the coronary artery bypass surgery study. Arteriosclerosis (1982) 2:208-215.
7. ILVESKOSKI E, PEROLA M, LEHTIMÄKI T et al.: Age-dependent association of apolipoprotein E genotype with coronary and aortic atherosclerosis in middle-aged men - an autopsy study. Circulation (1999) 100:608-613.
8. HWANG DM: A genome based resource of molecular cardiovascular medicine. Circulation (1997) 96:4146-4203. Complete overview on genes involved in cardiovascular disease and a resource for internet access of genome data.
9. WANG DG, FAN JB, SIAO CJ et al.: Large-scale identification, mapping, and genotyping of single-nucleotide polymorphisms in the human genome. Science (1998) 280:1077-1082. Excellent report on genes associated with cardiovascular disease and on genetic variation.
10. CAMBIEN F, POIRIER O, NICAUD V et al.: Sequence diversity in 36 candidate genes for cardiovascular disorders. Am. J. Hum. Genet. (1999) 65:183-191. Major contribution with systematic screening of genetic diversity in 36 candidate genes for cardiovascular disease.
11. CARGILL M, ALTSCHULER D, IRELAND J et al.: Characterization of single-nucleotide polymorphisms in coding regions of human genes. Nature Genet. (1999) 22:231-238. This systematic screening for polymorphisms in the coding region of 114 genes relevant to cardiovascular disease, endocrinology and neuropsychiatry provides a fundamental description of sequence variation in human genes.
12. HALUSHKA MK, FAN J-B, BENTLEY K et al.: Patterns of single-nucleotide polymorphisms in candidate genes for blood-pressure homeostasis. Nature Genet. (1999) 22:239-247. Excellent systematic search of single-nucleotide polymorphisms in 75 candidate genes for blood pressure homeostasis and hypertension which provides a fundamental description on human allelic variation and the frequency of protein-altering polymorphisms.
13. SPIELMAN RS, MCGINNIS RE, EWENS WJ: Transmission test for linkage disequilibrium: the insulin gene region and insulin-dependent diabetes mellitus (IDDM). Am. J. Hum. Genet. (1993) 52:506-513.
14. SPIELMAN RS, EWENS WJ: A sibship test for linkage in the presence of association: the sib transmission/disequilibrium test. Am. J. Hum. Genet. (1998) 62:450-458.
15. KEE F, AMOUYEL P, FUMERON F: Lack of association between genetic variations of apo A-I-C-III-A-IV gene cluster and myocardial infarction in a sample of European male: ECTIM study. Atherosclerosis (1999) 145:187-195.
16. HEGELE RA, HUANG L-S, HERBERT PN et al:. Apolipoprotein B-gene DNA polymorphisms associated with myocardial infarction. New Engl. J. Med. (1986) 315:1509-1515.
17. TURNER PR, TALMUD PJ, VISVIKIS S, EHNHOLM C, TIRET L: DNA polymorphisms of the apolipoprotein B gene are associated with altered plasma lipoprotein concentrations but not with perceived risk of cardiovascular disease: European Atherosclerosis Research Study. Atherosclerosis (1995) 116:221-234.
18. MARSHALL HW, MORRISON LC, WU LL et al.: Apolipoprotein polymorphisms fail to define risk of coronary artery disease - results of a prospective, angiographically controlled study. Circulation (1994) 89:567-577.
19. DAVIGNON J, GREGG RE, SING CF: Apolipoprotein E polymorphism and atherosclerosis. Arteriosclerosis (1988) 8:1-21. Authoritative and comprehensive review of the apo E polymorphism and atherosclerosis.
20. EICHNER JE, KULLER LH, ORCHARD TJ, GRANDITS GA, MCCALLUM LM, NEATON JD: Relation of apolipoprotein E phenotype to myocardial infarction and mortality from coronary artery disease. Am. J. Cardiol. (1993) 71:160-165.
21. LENZEN HJ, ASSMANN G, BUCHWALSKY R, SCHULTE H: Association of apolipoprotein E polymorphism, low density lipoprotein cholesterol, and coronary artery disease. Clin. Chem. (1986) 32:778-781.
22. WILSON PWF, MYERS RH, LARSON MG, ORDOVAS JM, WOLF PA, SCHAEFER EJ: Apolipoprotein E alleles, dyslipidemia, and coronary heart disease - the Framingham Offspring Study. JAMA (1994) 272:1666-1671.
23. FISHER RM, HUMPHRIES SEA, TALMUD PJ: Common variation in the lipoprotein lipase gene: effects on plasma lipids and risk of atherosclerosis. Atherosclerosis (1997) 135:145-159.
24. GERDES C, FISHER RM, NICAUD V et al. (ON BEHALF OF THE EARS GROUP): Lipoprotein lipase variants D9N and N291S are associated with increased plasma triglyceride and lower high-density lipoprotein cholesterol concentrations - studies in the fasting and postprandial states: The European Atherosclerosis Research Studies. Circulation (1997) 96:733-740.
25. 291Ser) in lipoprotein lipase is associated with increased risk of ischemic heart disease. J. Clin. Invest. (1997) 99:1606-1613.
26. GALTON DJ, MATTU R, NEEDHAM EWA, CAVANNA J: Identification of putative beneficial mutations for lipid transport. J. Gastroenterol. (1996) 34(Suppl. 3):56-58.
27. WITTRUP HH, TYBJAERG-HANSEN A, NORDESTGAARD BG: Lipoprotein lipase mutations, plasma lipids and lipoproteins, and risk of ischemic heart disease. Circulation (1999) 99:2901-2907.
28. CLARK AG, WEISS KM, NICKERSON DA et al.: Haplotype structure and population genetic inferences from nucleotide-sequence variation in human lipoprotein lipase. Am. J. Hum. Genet. (1998) 63:595-612. Important and fundamental report on the genetic diversity among different populations exemplified by full-scale detection of the allelic variation in the lipoprotein lipase gene.
29. JANSEN H, VERHOEVEN AJM, WEEKS L et al.: Common C-to-T substitution at position -480 of the hepatic lipase promoter associated with a lowered lipase activity in coronary artery disease patients. Arterioscler. Thromb. Vasc. Biol. (1997) 17:2837-2842.
30. MCPHERSON R, GRUNDY SM, GUERRA R, COHEN JC: Allelic variation in the gene encoding the cholesteryl ester transfer protein is associated with variation in the plasma concentration of cholesteryl ester transfer protein. J. Lipid Res. (1996) 37:1743-1748.
31. KUIVENHOVEN JA, DEKNIJFF P, BOER JMA et al.: Heterogeneity at the CETP gene locus - influence on plasma CETP concentrations and HDL cholesterol levels. Arterioscler. Thromb. Vasc. Biol. (1997) 17:560-568.
32. KUIVENHOVEN JA, JUKEMA JW, ZWINDERMAN AH et al. (FOR THE REGRESSION GROWTH EVALUATION STATIN STUDY GROUP): The role of a common variant of the cholesteryl ester transfer protein gene in the progression of coronary atherosclerosis. New Engl. J. Med. (1998) 338:86-93.
33. A2. Tissue Antigens (1995) 46:374-381.
34. WEISS EJ, BRAY PF, TAYBACK M et al.: A polymorphism of a platelet glycoprotein receptor as an inherited risk factor for coronary thrombosis. New Engl. J. Med. (1996) 334:1090-1094.
35. b) positive platelets in patients with cardiovascular disease. Eur. Heart J. (1999) 20:742-747.
36. a2 polymorphism - the Framingham Offspring study. Arterioscler. Thromb. Vasc. Biol. (1999) 19:1142-1147.
37. a2) is an inherited risk factor for premature myocardial infarction in coronary artery disease. Thromb. Haemost. (1998) 79:731-735.
38. a2) of the glycoprotein IIIa (GPIIIa) receptor is not related to myocardial infarction in the ECTIM study. Thromb. Haemost. (1997) 77:1179-1181.
39. LAULE M, CASCORBI I, STANGL V et al.: A1/A2 polymorphism of glycoprotein IIIa and association with excess procedural risk for coronary catheter interventions: a case-controlled study. Lancet (1999) 353:708-712.
40. a1/a2 polymorphism of platelet glycoprotein IIIa and risks of myocardial infarction, stroke, and venous thrombosis. Lancet (1997) 349:385-388.
41. ARDISSINO D, MANNUCCI PM, MERLINI PA et al.: Prothrombotic genetic risk factors in young survivors of myocardial infarction. Blood (1999) 94:46-51. Excellent study approach towards identification of genetic variation in genes of the coagulation pathway in premature MI and their interaction with environmental factors.
42. 2 gene coding sequence. Blood (1997) 89:1939-1943.
43. 807T gene polymorphism with nonfatal myocardial infarction in younger patients. Blood (1999) 93:2449-2453.
44. MEADE TW, MELLOWS S, BROZOVIC M et al.: Haemostatic function and ischaemic heart disease: principal results of the Northwick Park Heart study. Lancet (1986) 2:533-537.
45. VAN DER BOM JG, DE MAAT MPM, BOTS ML: Elevated plasma fibrinogen - cause or consequence of cardiovascular disease. Arterioscler. Thromb. Vasc. Biol. (1998) 18:621-625.
46. BEHAGUE I, POIRIER O, NIGAUD V et al.: β fibrinogen gene polymorphisms are associated with plasma fibrinogen and coronary artery disease in patients with myocardial infarction. Circulation (1996) 93:440-449.
47. GARDEMANN A, SCHWARTZ O, HABERBOSCH W et al.: Positive association of the β fibrinogen H1/H2 gene variation to basal fibrinogen levels and to the increase in fibrinogen concentration during acute phase reaction but not to coronary artery disease and myocardial infarction. Thromb. Haemost. (1997) 77:1120-1126.
48. 455A β-gene) is associated with differences in plasma fibrinogen levels in young men and women from different regions in Europe - evidence for gender-genotype-environment interaction. Arterioscler. Thromb. Vasc. Biol. (1995) 15:96-104.
49. FOLSOM AR, WU KK, ROSAMOND WD, SHARRETT AR, CHAMBLESS LE: A prospective study of hemostatic factors and incidence of coronary heart disease: the Atherosclerosis Risk in Communities (ARIC) study. Circulation (1997) 96:1102-1108.
50. HEINRICH J, BALLEISEN L, SCHULTE H, ASSMANN G, VAN DE LOO J: Fibrinogen and Factor VII in the prediction of coronary risk: results from the PROCAM study in healthy men. Arterioscler. Thromb. (1994) 14:54-59.
51. IACOVIELLO L, DI CASTELNUOVO A, DE KNIJFF P et al.: Polymorphisms in the coagulation Factor VII gene and the risk of myocardial infarction. New Engl. J. Med. (1998) 338:79-85.
52. BERNHARDI F, ARCIERI P, BERTINA M et al.: Contribution of Factor VII genotype to activated FVII levels - differences in genotype frequencies between Northern and Southern European populations. Arterioscler. Thromb. Vasc. Biol. (1997) 17:2548-2553.
53. WANG XL, WANG J, MCCREDIE RM, WILCKEN DEL: Polymorphisms of Factor V, Factor VII, and fibrinogen genes - relevance to severity of coronary artery disease. Arterioscler. Thromb. Vasc. Biol. (1997) 17:246-251.
54. DOGGEN CJM, CATS VM, BETINA RM, REITSMA PH, VANDENBROUCKE JP, ROSENDAAL FR: A genetic propensity to high Factor VII is not associated with the risk of myocardial infarction in men. Thromb. Haemostas. (1998) 80:281-285.
55. LANE A, GREEN F, SCARABIN PY et al.: Factor VII arg/GIn-353 polymorphism determines factor VII coagulant activity in patients with myocardial infarction (MI) and control subjects in Belfast and in France but is not a strong indicator of MI risk in the ECTIM study. Atherosclerosis (1996) 119:119-127.
56. FENG DL, LINDPAINTNER K, LARSON MG et al.: Factor VII gene polymorphism and cardiovascular disease: the Framingham Heart Study [abstract]. Circulation (1998) 98(Suppl. I):459.
57. MANNUCCI PM, MARI G, MERATI G et al.: Gene polymorphisms predicting high plasma levels of coagulation and fibrinolysis proteins - a study in centenarians. Arterioscler. Thromb. Vasc. Biol. (1997) 17:755-759.
58. HAMSTEN A, WIMAN B, DEFAIRE U, BLOMBACK M: Increased plasma levels of a rapid inhibitor of plasminogen activator inhibitor in young survivors of myocardial infarction. New Engl. J. Med. (1985) 313:1557-1563.
59. YE S, GREEN FR, SCARABIN PY et al.: The 4G/5G genetic polymorphism in the promoter of the plasminogen activator inhibitor (PAI-1) gene is associated with differences in plasma PAI-1 activity but not with risk of myocardial infarction hi the ECTIM study. Thromb. Haemost. (1995) 74:837-841.
60. RIDKER PM, HENNEKENS CH, LINDPAINTNER K, STAMPFER MJ, MILETICH JP: Arterial and venous thrombosis is not associated with the 4G/5G polymorphism in the promoter of the plasminogen activator inhibitor gene in a large cohort of US men. Circulation (1997) 95:59-62.
61. FENG DL, TOFLER GH, LARSON MG et al.: The plasminogen activator inhibitor-1 gene 4G/5G polymorphism and cardiovascular disease: the Framingham heart study [abstract]. J. Am. Coll. Cardiol. (1999) 33(Suppl. IA):288A-289A.
62. KOHLER HP, STICKLAND MH, OSSEI-GERNING N, CARTER A, MIKKOLA H, GRANT PJ: Association of a common polymorphism in the Factor XIII gene with myocardial infarction. Thromb. Haemost. (1998) 79:8-13.
63. KANGSADALAMPAI S, BOARD PG: The Val34Leu polymorphism in the A subunit of coagulation Factor XIII contributes to the large normal range in activity and demonstrates that the activation peptide plays a role in catalytic activity. Blood (1998) 92:2766-2770.
64. RIGAT B, ALHENC-GELAS F, CAMBIEN F, SOUBRIER F: An insertion/deletion polymorphism in the angiotensin I-converting gene accounting for half the variance of serum levels. J. Clin. Invest. (1990) 86:1343-1346.
65. CAMBIEN F, POIRIER O, LECERF L et al.: Deletion polymorphism in the angiotensin-converting enzyme is a potent risk factor for myocardial infarction. Nature (1992) 359:641-644. Although polymorphisms have been studied for a long time by geneticists, this report on a clinical association between a genetic variation of the ACE gene and MI risk, started an entire new field of risk factor research in clinical medicine.
66. WINKELMANN BR, NAUCK M, KLEIN B et al.: Deletion polymorphism of the angiotensin I-converting enzyme gene is associated with increased plasma angiotensin-converting enzyme activity but not with increased risk for myocardial infarction and coronary artery disease. Ann. Intern. Med. (1996) 125:19-25.
67. AGERHOLM-LARSEN B, NORDESTGAARD BG, STEFFENSEN R, SORENSEN TIA, LENSEN G, TYBJOERKHANSEN A: ACE gene polymorphism: ischemic heart disease and longevity in 10150 individuals - a case-referent and retrospective cohort study based on the Copenhagen City Heart Study. Circulation (1997) 95:2358-2367.
68. HOLMER SR, HENGSTENBERG C, MAYER B et al.: No association of the I/D polymorphism of the angiotensin-converting enzyme with myocardial infarction in 4941 probands [abstract]. Eur. Heart J. (1999) 20(abstract Suppl.):143.
69. KEAVNEY B, MCKENZIE C, PARISH S et al.: Large-scale test of hypothesized associations between the ACE I/D polymorphism and MI in over 10 000 cases and controls [abstract]. Eur. Heart J. (1999) 20(abstract Suppl.):143.
70. CORVOL P, JEUNEMAITRE X: Molecular genetics of human hypertension: role of angiotensinogen. Endocrine rev. (1997) 18:662-677. Authoritative review of the molecular genetics of angiotensinogen.
71. KUNZ R, KREUTZ R, BEIGE J, DISTLER A, SHARMA AM: Association between the angiotensinogen 235T-variant and essential hypertension in whites - a systematic review and methodological appraisal. Hypertension (1997) 30:1331-1337.
72. KATSUYA T, KOIKE G, YEE TW et al.: Association of angiotensinogen gene T235 variant with increased risk of coronary heart disease. Lancet (1995) 345:1600-1603.
73. WINKELMANN BR, RUSS AP, NAUCK M et al.: Angiotensinogen M235T polymorphism is associated with plasma angiotensinogen and cardiovascular disease. Am. Heart J. (1999) 137:698-705.
74. TIRET L, RICARD S, POIRIER O et al.: Genetic variation at the angiotensinogen locus in relation to high blood pressure and myocardial infarction: the ECTIM study. J. Hyperten. (1995) 13:311-317.
75. LUDWIG EH, BORECKI IB, ELLISON RC et al.: Associations between candidate loci angiotensin-converting enzyme and angiotensinogen with coronary heart disease and myocardial infarction: the NHLBI family heart study. Ann. Epidemiol. (1997) 7:3-12.
76. BRATTSTRÖM L, WILCKEN EL, ÖHRVIK J, BRUDIN L: Common methylenetetrahydrofolate reductase gene mutation leads to hyperhomocysteinemia but not to vascular disease. Circulation (1998) 98:2520-2526.
77. 677T mutation, plasma homocysteine, folate in subjects from northern Italy with and without angiographically documented severe coronary atherosclerotic disease: evidence for an important genetic-environmental interaction. Blood (1998) 91:4158-4163.
78. KLUIJTMANS LAJ, KASTELEIN JJP, LINDEMANS J et al.: Thermolabile methylenetetrahydrofolate reductase in coronary artery disease. Circulation (1997) 96:2573-2577.
79. 677T gene polymorphism is associated with the extent of coronary atherosclerosis in patients at high risk for coronary artery disease. Eur. Heart J. (1999) 20:584-592.
80. 677T mutation. Arterioscler. Thromb. Vasc. Biol. (1996) 16:878-882.
81. KHOURY MJ, WAGENER DK: Epidemiological evaluation of the use of genetics to improve the predictive value of disease risk factors. Am. J. Hum. Genet. (1995) 56:835-844.
82. THOMAS AE, GREEN FR, HUMPHRIES SE: Association of genetic variation at the beta-fibrinogen gene locus and plasma fibrinogen levels: interaction between allele frequency of the G/A-455 polymorphism, age and smoking. Clin. Genet. (1997) 34:553-558.
83. THOMAS AE, GREEN FR, KELLEHER CH et al: Variation at the promoter of the β fibrinogen gene is associated with plasma fibrinogen levels in smokers and non-smokers. Thromb. Haemost. (1991) 65:487-490.
84. CAMBIEN F, POIRIER O, MALLET C, TIRET L: Coronary heart disease and genetics: an epidemiologist' S view. Mol. Med. Today (1997) 1:197-203.
85. FRIEDLANDER Y, ELKANA Y, SINNREICH R, KARK JD: Genetic and environmental sources of fibrinogen variability in Israeli families: the Kibbutzim family study. Am. J. Hum. Genet. (1995) 56:1194-1206.
86. HELLER DA, PEDERSEN NL, DEFAIRE U, MCCLEARN GE: Genetic and environmental correlations among serum lipids and apolipoproteins in elderly twins reared together and apart. Am. J. Hum. Genet. (1994) 55:1255-1267.
87. JARVIK GP, GOODE EL, AUSTIN MA et al.: Evidence that the apolipoprotein E-genotype effects on lipid levels can change with age in males: a longitudinal analysis. Am. J. Hum. Genet. (1997) 61:171-181.
88. BARRET-CONNOR E: Sex differences in coronary heart disease - Why are women so superior [The 1995 Ancel Keys Lecture]. Circulation (1997) 95:252-264.
89. BRZUSTOWICZ LM, MERETTE C, XIE X, TOWNSEND L, GILLIAM TC, OTT J: Molecular and statistical approaches to detection and correction of errors in genotype databases. Am. J. Hum. Genet. (1993) 53:1137-1145.
90. RISCH N, MERIKANGAS K: The future of genetic studies of complex human diseases. Science (1996) 273:1516-1517.
91. KRUGLYAK L, LANDER ES: High-resolution genetic mapping of complex traits. Am. J. Hum. Genet. (1995) 56:1212-1223.
92. DEAN M, STEPHENS JC, WINKLER C et al.: Polymorphic admixture typing in human ethnic populations. Am. J. Hum. Genet. (1994) 55:788-808.
93. XIONG M, JIN L: Comparison of the power and accuracy of biallelic and microsatellite markers in population-based gene-mapping methods. Am. J. Hum. Genet. (1999) 64:629-640.
94. STEPHENS JC, BRISCOE D, O'BRIEN SJ: Mapping by admixture linkage disequilibrium in human populations: limits and guidelines. Am. J. Hum. Genet. (1994) 55:809-824.
95. KRUGLYAK L: Prospects for whole-genome linkage disequilibrium mapping of common disease genes. Nature Genet. (1999) 22:139-144.
96. TU IP, WHITTEMORE AS: Power of association and linkage tests when the disease alleles arc unobserved. Am. J. Hum. Genet. (1999) 64:641-649.
97. FUNKE H, ASSMANN G: Strategies for the assessment of genetic coronary artery disease risk. Curr. Opin. Lipidol. (1999) 10:285-291.
98. BEAUDET AL: Making genomic medicine a reality [1998 ASHG presidential address]. Am. J. Hum. Genet. (1999) 64:1-13.
99. FLEISS JL, TYTUN A, URY HK: A simple approximation for calculating sample sizes for comparing independent. Biometrics (1980) 36:343-346.